Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
A 24-year-old patient was first evaluated at our Institution 6 years ago because of 6-month history of paroxysmal atrial fibrillation and a suspicion of restrictive cardiomyopathy. The patient complained of decreased exercise tolerance and palpitations. Physical examination at the time revealed a tall man (179 cm, 84kg, BSA 2 m2) with barrel chest. Accentuated pulmonary component of the second tone was found. The patient was in sinus rhythm, right axis deviation and left atrial enlargement were present in 12-lead standard ECG. Chest X-ray revealed increased heart silhouette, left atrial enlargement and mild congestion in the pulmonary circulation. In echocardiographic examination, the sizes of both ventricles and right atrium were normal, however there was a significant left atrial enlargement (62 mm x 48 mm in 4-chamber view). LV and RV systolic functions were normal. There was no endocardial thickening. A Doppler echocardiographic study revealed a mitral restrictive filling pattern (E/A=2.7) and increased RVSP – approximately 45 mmHg (tricuspid regurgitation was slight), pulmonary acceleration time was 90 ms. In TEE there were no heart defects as well, proximal parts of coronary arteries were normal. Subsequently cardiac MR and chest CT were performed without revealing any pericardial pathology. There was no evidence of any systemic disease in the patient. In 24-hour Holter monitoring, the mean heart rate was 77 bpm, there were no pauses, no arrhythmia. Alfa-galactosidase activity in serum and leukocytes was normal, CK activity was normal 82 U/l, serum ferrum concentration was 205 μg/dl. In an exercise stress test, the patient attained 10.9 METs with Bruce protocol, of note he had prolonged postexertional tachycardia, 5 minutes after the exercise his heart rate in sinus rhythm was 110-120 bpm.
Question 1: Based on the presented data, what other examinations could have been performed in the patient to clarify his condition?
For another 3 years, the patient suffered from recurrent episodes of paroxysmal atrial fibrillation with rapid ventricular response while on bisoprolol, uptitrated up to 10 mg and amiodarone were started. In addition, there was progression in his heart failure symptoms, the patient dropped out of his university studies (computer science).
Physically, jugular venous distention appeared, especially during effort, and the patient’s head became oedematous at faster walk. In addition, mild hepatomegaly was present, there was neither ascites, nor ankle edema. Since then, to control congestive symptoms, the patient required 2 diuretics (frusemide and hydrochlorothiazide), spironolactone 25-50 mg. Bisoprolol at 10 mg and amiodarone were continued. Standard 12-lead ECG revealed: sinus rhythm 72 bpm, minor right axis deviation, left atrial enlargement, incomplete right bundle branch block RSR’ in V1, tall R waves in RV leads suggestive of right ventricular hypertrophy. In echocardiography, a further increase in LA size (29 cm2), restrictive filling pattern, RV systolic pressure from slight TR was 100 mmHg. A cardiopulmonary study in this young man showed MVO2 of 22.3 ml/kg/min (50% of reference) and MVO2 at AT was 16.7ml/kg/min, there was a drop in systemic pressure from 170 to 150 mmHg during maximal exercise, and his maximum METs was 6.4. At that time (in 2006), a first approach was made to define contraindications for HTX better, and right heart pressures were as follows: PCWP 43/43/42 mmHg, PA 71/41/53 mmHg, thus the transpulmonary gradient (TG) was 11 mmHg, RA: 12/8/8 mmHg, RV: 71/5-13 mmHg and LV: 100/24-34mmHg. CO – 5.8l/min, PAR 1.88 Wood units, and SVR – 13.7 Wood units. His coronary angiography was normal. The decision was to repeat right heart catheterization in 6-12 months. In 2007, more pronounced limitation of exercise capacity (swelling of his head at mild exercise), NYHA III, a drop in MVO2 -20.5 ml/kg/min, MVO2 at AT 13.3 ml/kg/min, PAP 57/23/37 mmHg, increased TG of 15 mmHg and PVR – 2.6 Wood units.
Question 2: Would you have referred the patient for heart transplantation at the time, knowing the criteria for disqualification from the procedure?
The patient was not entirely convinced to have cardiac transplant since he still could cycle on the level surface slowly for 1-2 hours. After a long discussion with the patient and his parents, we accepted the decision. Soon, the patient developed thyreotoxicosis due to amiodarone treatment that had to be controlled with thyreostatics. At the time, the patient was in atrial fibrillation, amiodarone was continued to control rapid ventricular response, he was hospitalized 3 times due to worsening of heart failure. Once the patient returned to euthyreosis, he spontaneously converted into sinus rhythm (Fig. 1).
Fig. 1: 12-lead standard ECG: sinus rhythm 62 bpm, right axis deviation, biatrial enlargement, RV hypertrophy, RSR’ V1, Q waves in leads II,III, aVF QRS=120ms, QT 490ms, ST-T changes in infero-lateral leads.
In 2009, there was a significant deterioration in exercise capacity, the patient was unwilling to leave his place. CMR was performed (Fig. 2) showing biatrial enlargement (LA>>RA), both ventricles of normal size and contracting well LVEF 69%, RVEF 56%; corrected LV mass was 71 g/m2, N:59-93; corrected RV mass was at the upper limit of normal: 28g/m2, N:14-30, myocardial thickness: IVSD 12, PW-9mm, of interest no late enhancement after gadolinium injection was found.
Fig. 2 - MRI four-chamber CINE SSFP view - large dilatation of both atria (LA>>RA) with nondilated ventricles.
His Nt-proBNP level was not high (388 ng/ml), and the patient had detectable troponin I of 0.04 ng/ml. By the end of 2009, MVO2 was 14 ml/kg/min, and together with the patient, we decided once more to approach the issue of HTX, this time with the assessment of pulmonary vascular reactivity. During sinus rhythm of 70 bpm, right heart catheterization demonstrated again increased pulmonary artery pressures (PAP 71/29/47 mmHg), pulmonary capillary wedge pressures (PCWP 31/39/28 mmHg), thus TG was 19 mmHg. Cardiac output was normal (CO – 6.2 l/min), and pulmonary vascular resistance was increased (PVR – 2.8 Wood units), however SVR was normal: 12.4 Wood units. After aerolised iloprost inhalation TG dropped from 19 to 14 mmHg, but pulmonary artery systolic pressure was 64 mmHg. Due to the presence of pulmonary hypertension, we introduced sildenafil at 12.5 mg po, but after the second dose the patient developed atrial fibrillation and needed a cardioversion to return to sinus rhythm. No further attempts were made.
Question 3: Would you have referred the patient for heart transplantation at this time point?
What other examinations could have been performed in the patient?
The patient could have had endomyocardial biopsy performed. According to the guidelines (1), EMB is reasonable in the setting of heart failure associated with restrictive cardiomyopathy (Class of Recommendation IIa, Level of Evidence C). The first indication would have been to exclude systemic infiltrative disorders or storage diseases that could not be diagnosed otherwise, namely with the examination of extracardiac tissues, fluids. In our patient, there was neither Fabry disease, nor hemochromatosis, nor systemic diseases. There was no thickening of the myocardial walls, rendering infiltrative disorders rather unlikely. The use of both MRI and CT limited the significance of endomyocardial biopsy as a helpful tool to exclude pericardial diseases. In addition, there was no late enhancement after gadolinium injection showing lack of any evidence of structural damage of the myocardium. CPK was normal, thus rendering significant associated myopathy less possible.
Other important issues in restrictive cardiomyopathy are genetic studies (2-6). Thanks to the courtesy of Prof. Eloisa Arbustini, in the Pavia Centre for Inherited Cardiovascular Diseases, mutations in the following genes were excluded in the patient: MYH7, MYBPC3, TNNT2, TNNI3. Mutations in genes coding for other proteins like, desmin (DES) and alpha cardiac actin (ACTC) have also been associated with restrictive cardiomyopathy (5-6).
Question 2 and 3:
Would you have referred the patient for heart transplantation at the time, knowing the criteria for disqualification from the procedure?
Current guidelines state that heart transplantation should be considered in patients with the end-stage heart failure, with no serious co-morbidity and no alternative treatment options (7). Contraindications include irreversible high pulmonary vascular resistance (6-8 Wood units) and TG > 15 mmHg. There is no guideline how to approach patients who develop contraindications for heart transplantation first and indications for the procedure significantly later. This renders them ineligible for cardiac transplantation. A vasodilator challenge should be made when the pulmonary artery systolic pressure is ≥50 mmHg and either TG is ≥15 mmHg or PVR is >3 Wood units. In our patient, TG dropped from 19 to 14 mmHg, however PASP remained high >60 mmHg. ISHLT guidelines for listing patients for heart transplantation as relative contraindications show PAS exceeding 60 mmHg in conjunction with one of the three parameters (PVR> 5 Wood units, PVRI >6 or TG exceeding 16-20 mmHg) as important factors increasing the risk for early right heart failure and early death (8).
Therefore, we decided to try oral vasodilator, however due to most probably normal systemic vascular resistance – the attempt in the patient failed. Our patient was disqualified from HTX. Our cardiac surgeons considered him as being at too high a risk for developing right heart failure directly after HTX. A young doctor (LM) advised the patient to take Magnesium 2 x 0.5g in addition to his medication that was constant for the previous year apart from slight modifications of diuretics dosage, amiodarone according to QTc interval and serum concentration, acenocoumarol according to INR and kalium dosage).
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 BIOT
06903Sophia Antipolis, FR
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved